Key result
Sacubitril/valsartan was associated with a lower risk of cardiovascular mortality or heart failure-related hospitalization compared to enalapril in patients with heart failure (HR 0.58).
Why the study?
The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored.
Does sacubitril/valsartan reduce the composite of cardiovascular mortality or heart failure-related hospitalization in patients with heart failure compared to enalapril?
Cohort (n=3,237)
Yes
Does sacubitril/valsartan reduce the composite of cardiovascular mortality or heart failure-related hospitalization in patients with heart failure compared to enalapril?
Hazard Ratio: 0.58 (95% CI 0.45–0.75)
Absolute Event Rate: 32.6% vs 47.3%
In a real-world Asian cohort, sacubitril/valsartan was associated with significantly improved survival and reduced heart failure-related hospitalizations compared to enalapril, including in older patients.
May support use in real-world Asian cohorts; extends trial data but leaves open prospective confirmation.
Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored. We aimed to investigate the risk of hospitalization and mortality with the use of sacubitril/valsartan vs. enalapril in patients with heart failure. Methods: This was a population-based cohort study using the Hong Kong-wide electronic healthcare database. Patients diagnosed with heart failure and newly prescribed sacubitril/valsartan or enalapril between July 2016 and June 2019 were included. The risk of primary composite outcome of cardiovascular mortality or heart failure-related hospitalization, all-cause hospitalization, heart failure-related hospitalization, cardiovascular mortality and all-cause mortality were compared using Cox regression with inverse probability treatment weighting. Additional analysis was conducted by age stratification. Results: Of the 44,503 patients who received sacubitril/valsartan or enalapril, 3,237 new users (sacubitril/valsartan, n = 1,056; enalapril, n = 2,181) with a diagnosis of heart failure were identified. Compared with enalapril, sacubitril/valsartan users were associated with a lower risk of primary composite outcome [hazard ratio (HR) 0.58; 95% confidence interval (CI), 0.45–0.75], heart failure-related hospitalization (HR 0.59; 95% CI, 0.45–0.77), all-cause mortality (HR 0.51; 95% CI, 0.36–0.74) and borderline non-significant reductions in all-cause hospitalization (HR 0.85; 95% CI, 0.70–1.04) and cardiovascular mortality (HR 0.63; 95% CI, 0.39–1.02). The treatment effect of sacubitril/valsartan remains unaltered in the patient subgroup age ≥ 65 years (73%). Conclusions: In real-world settings, sacubitril/valsartan was associated with improved survival and reduced heart failure-related hospitalization compared to enalapril in Asian patients with heart failure. The effectiveness remains consistent in the older population.
No takes yet. Share an insight, caveat, or question.
Pathadka et al. (2021) conducted a cohort in Heart failure (n=3,237). Sacubitril/valsartan vs. Enalapril was evaluated on Composite of death from cardiovascular causes or heart failure-related hospitalization (HR 0.58, 95% CI 0.45-0.75). Sacubitril/valsartan was associated with a lower risk of cardiovascular mortality or heart failure-related hospitalization compared to enalapril in patients with heart failure (HR 0.58).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: